Cardiac Dimensions Secures Financing for Studies of Carillon Mitral Contour System


April 26, 2018—Cardiac Dimensions, Inc. announced that it has closed a $39 million Series B financing, which will be used to continue to build clinical evidence for the company's Carillon mitral contour system for the treatment of functional mitral regurgitation (FMR) in patients with heart failure. Clinical activities include continuing the United States pivotal CARILLON trial and completing the follow-up and publication of the randomized, double-blinded REDUCE FMR global study.

According to the company, the Carillon system is designed to offer physicians a safe and easy-to-use option to treat patients earlier in their disease diagnosis, including those with lesser degrees of FMR (MR grade 2+), to slow disease progression and stabilize or improve quality of life.

The Carillon mitral contour system is limited to investigational use in the United States. The Carillon system has CE Mark approval and is available in certain European markets and other key geographies.

The financing round includes new investor, Australia-based Hostplus, venture debt from Oxford Finance LLC, as well as support from existing investors M. H. Carnegie & Co., Arboretum Ventures, Lumira Capital, LSP Health Economics Fund, and Aperture Venture Partners.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.